Edwards Lifesciences Reports Q3 Earnings Beat and Raises Sales Growth Guidance
Edwards Lifesciences (EW) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a Non-GAAP earnings per share (EPS) of $0.80, surpassing estimates by $0.06, while total revenue reached $1.72 billion, representing an 11% year-over-year increase and beating projections by $40 million. Driven by strong performance, the company has raised its full-year total sales growth guidance to approximately 11.5%, up from its previous range of 10% to 11%. This upward revision reflects robust demand within its core segments, specifically highlighting momentum in Transcatheter Aortic Valve Replacement (TAVR) sales.
Tickers: $EW
Topics: earnings beat guidance increase revenue growth TAVR sales
Read the full article at Seeking Alpha
Part of the story Redwire Shares Drop Following Q3 2026 Earnings Miss (29 articles)